Clinical Computational Oncology @DanaFarber @harvardmed @broadinstitute | Chief AI Officer & PopSci | Prev: @Stanford @UCLA @UCSF | Disc: https://xitter.cf/t.co/EmrHxvg76N
Boston, MA
Joined June 2010
- Tweets3.3K
- Following2K
- Followers9.1K
- Likes17.9K
Eli Van Allen retweeted
We are now accepting applications for the T32 postdoctoral fellowship training program: Training in Oncology Population Sciences (TOPS)
Applications are due 12/16 and accepted fellows will begin their training in September 2027. TOPSPostdoc.org
Eli Van Allen retweeted
In case anyone is running agents and wondering if you can leave them running on a holiday, know that Chabad is on the case!
chabad.org/library/article_c…
Eli Van Allen retweeted
New work from Pasi A. Jänne, us, and 23andme; led by Jackie LoPiccolo and Steven Micheletti. Characterizing a highly penetrant germline founder mutation for lung cancer.
An inherited genetic mutation may increase lung cancer risk among people who have never smoked, according to a new Science study.
By tracing the ancestry of people carrying the rare EGFR T790M variant, researchers uncovered a shared genetic legacy extending back hundreds of years and concentrated in the southeastern United States.
Learn more in this week’s issue: scim.ag/46q1kUC
ALT An inherited mutation in the EGFR gene (EGFR T790M) increases lung cancer risk. In this illustration, lungs merge with a map of the United States, reflecting the geographic enrichment of the EGFR T790M mutation. By tracing the ancestry of people carrying this mutation, researchers uncovered a shared genetic legacy extending back hundreds of years and concentrated in the southeastern United States. Illustration: Oliver Uberti
Eli Van Allen retweeted
🚨We are hiring! 🚨
The Department of Biostatistics @HarvardChan and the Department of Data Science @DanaFarber are recruiting a tenure-track Assistant/Associate Professor in statistics or machine learning with interests in single-cell or spatial genomics.
Link below 👇
Eli Van Allen retweeted
Here's our latest in @cellpressblue. In collaboration with @VanAllenLab and @mouwlab, we asked a simple question:
Why do some muscle-invasive bladder cancers survive neoadjuvant chemotherapy? 🧵cell.com/cell-press-blue/ful…
Congrats to @JihyunkaLee et al!
Eli Van Allen retweeted
Very exciting new method for inferring latent disease trajectories, led by the tireless Dr. Urbut with Natarajan and Parmigiani labs. If you're considering a postdoc in this area talk to Sarah!
One of my first consults as a cardiology fellow: a 34-year-old, textbook MI. A day earlier, no risk model would have flagged him for prevention. That paradox has driven my work ever since — our models miss how disease actually evolves, dynamically, on top of a genetic background. @Nature nature.com/articles/s41586-0…
Eli Van Allen retweeted
One of my first consults as a cardiology fellow: a 34-year-old, textbook MI. A day earlier, no risk model would have flagged him for prevention. That paradox has driven my work ever since — our models miss how disease actually evolves, dynamically, on top of a genetic background. @Nature nature.com/articles/s41586-0…
Eli Van Allen retweeted
Please repost! We are seeking #PostDocs to join our lab in @YaleGenetics @YaleCancer @CancerYale to study #genetic and #host drivers of #PancreaticCancer and #LungCancer. Check out our newly updated website for more lab details! medicine.yale.edu/lab/muzumd…
Eli Van Allen retweeted
📣Delighted to share two new studies from our team
using germline genome sequencing 🧬
to understand #cancer #predisposition!
Interested? 🧵👇 for details
1/15
Eli Van Allen retweeted
Using burgers as a model system, a generative AI system rediscovers the classic Big Mac without explicit supervision and generates novel burgers optimized for deliciousness, sustainability, or nutrition, according to a paper in npj Science of Food. go.nature.com/3SU7JDQ
ALT This is figure 2, which shows rediscovering classic burger and discovering delicious burgers.
Eli Van Allen retweeted
1/ Results from #ARC20 trial are out in @Nature!
This trial evaluated the HIF-2α inhibitor Casdatifan in heavily pretreated advanced ccRCC and provides important insights into HIF-2α biology and response. This is the 2nd HIF2 inhibitor with enough activity to move to a pivotal study after Belzutifan, cementing the 2019 @nobelprize story with @kaelinlab et al
Check it out: nature.com/articles/s41586-0…
Eli Van Allen retweeted
We are hiring! We are specifically looking for a postgraduate associate - someone who has recently finished university and is ultimately looking to apply to medical school or graduate school.
It is a TWO YEAR clinical/translational position, where you will be interacting closely with patients, involved in translational clinical trials, and working hands on in the lab and with clinical databases.
The ideal candidate is a great communicator, organized, and enthusiastic about patient-oriented clinical and lab research. You will get dedicated mentoring not just on the science and clinic, but also on career/professional development as well.
We are looking for someone to start ASAP! More information here:
postdocs.yale.edu/posts/2026…
Please help to spread the word and RT!
@DrChoueiri @VanAllenLab @tompowles1 @YaleCancer @YaleMed @SmilowCancer @kidneycan @OncoAlert @OncLive @KidneyCancer @A_P_S_A @cure_today @yalepathology @Yale_Urology @DrYukselUrun @MarkDSiegel1 @OncBrothers @DrKarineTawagi
Eli Van Allen retweeted
Today at #AACR26: Noah Fields, MS, of @DanaFarber’s @VanAllenLab, presents findings from a familial cancer study suggesting that high-resolution germline genetic testing could benefit patients with familial cancer.
➡️ bit.ly/4crIeQl
Eli Van Allen retweeted
LBA1/Plenary #ASCO26: PROTEUS trial
Perioperative apalutamide + ADT vs. placebo + ADT with radical prostatectomy in HR localized or locally advanced PC
Our very own #DrMaryEllenTaplin from @DanaFarber_GU will take the stage at #ASCO26 and present phase 3 PROTEUS trial. This is a key multimodal treatment question and could shift the paradigm on how we think about systemic therapy in the perioperative setting. Dr Taplin has worked on countless Neoadjuvant Strategies in prostate cancer and it is rewarding to see her work materialize at the big stage !
@DanaFarber @DanaFarber_GU @ASCO @OncoAlert
Eli Van Allen retweeted
📣 We’re hiring a computational genomics postdoc! 📣
Our lab at @DanaFarber is looking for a postdoctoral fellow — details👇
Eli Van Allen retweeted
“This rare cancer, liposarcoma, gives us a unique opportunity to study what GLP-1 drugs do to cancer cells,” @DanaFarber’s Dr. Erica Pimenta tells @washingtonpost about her research into whether the weight-loss medications could be a treatment pathway.
Read more: bit.ly/4k08KUr
Eli Van Allen retweeted
This fall, when Jason Collins was given a terminal brain cancer diagnosis, his twin brother Jarron said to him, “You have to fight.” Jason nodded. “I know how to do that.” I have the privilege of helping @jasoncollins98 tell his story. espn.com/nba/story/_/id/4726…
Eli Van Allen retweeted
If you're a hematology nerd headed to Orlando, I'd love it if you put my talk on your radar:
"Sickle cell disease is associated with early-onset clonal hematopoiesis involving DNA damage response pathway mutations"
Saturday, December 6, 2025 at 9:30 AM
Eli Van Allen retweeted
I've consistently found working in academia to be incredibly rewarding. Having the opportunity to propose whatever crazy idea you have to be evaluated for funding by your peers -- three times a year every year! -- is a genuine miracle.
